Aytu Biopharma (AYTU) EBIT (2010 - 2026)

Aytu Biopharma (AYTU) has reported EBIT for 17 consecutive years, with -$4.1 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, EBIT fell 267.86% year-over-year to -$4.1 million in Q1 2026; TTM through Mar 2026 was -$15.2 million, a 512.07% decrease from a year earlier, with the FY2025 full-year figure at -$7.8 million, down 391.95% from the prior year.
• EBIT was -$4.1 million for Q1 2026 at Aytu Biopharma, down from -$2.0 million in the prior quarter.
• Over five years, EBIT peaked at $3.1 million in Q4 2023 and troughed at -$53.4 million in Q1 2022.
• A 5-year average of -$6.1 million and a median of -$1.8 million in 2022 frame the typical range for EBIT.
• Across the five-year window, EBIT slumped 1444.97% in 2024 and surged 251.6% in 2025, its largest moves.
• Over 5 years, EBIT stood at -$6.9 million in 2022, then soared by 145.81% to $3.1 million in 2023, then sank by 153.88% to -$1.7 million in 2024, then dropped by 16.22% to -$2.0 million in 2025, then sank by 106.29% to -$4.1 million in 2026.
• The last three EBIT figures came in at -$4.1 million (Q1 2026), -$2.0 million (Q4 2025), and -$1.5 million (Q3 2025), per Business Quant data.